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Summary
Objective The treatments of ischaemic heart disease have drastically changed due to the
developments in coronary-anterial bypass graft operations and coronary intervention pro-
cedures. The treatment outcomes of these procedures are compared using observational
data.
Method The data used are microdata from Surveys of Medical Care (SMC) in Japan
from 1992 to 1998, which are claim data, not using a randomized controlled trial. Hence,
endogeneity in the choice of treatment should be important and thus both the instrumental
variables method and the nonparametric propensity score matching method are adopted
for estimation.
Result Although the instrumental variables method and nonparametric propensity score
matching method produce different results in many cases, predominance of the latter over
the instrumental method is confirmed. Although claimed with some reservations, patients
treated with precutaneous transluminal coronary angioplasty (PTCA) have significantly
lower possibility of severe heart failure than those treated with coronary artery by-pass
grafting (CABG). The results of comparing invasive procedures with preserving treat-
ment depend on the existence of constraints. In data for more acute situations, invasive
procedures have a significantly higher possibility of severe heart failure than preserving
treatment.
Keywords: Ischaemic heart disease, Coronary intervention, Percutaneous transluminal
coronary angioplasty, Coronary aorta bypass grafting, Instrumental variables method, Non-
parametric propensity score matching method
1 Introduction
Heart disease is the second most common cause of death in Japan, and more than half these
deaths are caused by ischaemic heart disease. The risk factors include age, hyperlipidaemia,
smoking, hypertension, and the importance of ischaemic heart disease is naturally rising in
Japan.
Before the 1970s, the main treatments for ischaemic heath disease were conservative,
such as rest and medication. In the 1970s, treatment changed drastically with the develop-
ment of coronary artery bypass grafting (CABG) and coronary intervention using coronary
catheterization. These new treatments have decreased mortality from ischaemic heart dis-
ease, but they are invasive and expensive. Indications for these treatments have to be
considered carefully. Recently, the practice of evidence-based medicine (EBM) has been
established, and many randomized controlled studies are being performed for collecting
evidence of the outcomes of each treatment.
Some clinical studies of ischaemic heart disease have results contradicting other studies.
For example, some show evidence that percutaneous transluminal coronary angioplasty
(PTCA) has better outcomes than percutaneous transluminal coronary recanalization for
patients with acute myocardial infarction1), but others provide opposite evidence2). By in-
tegrating many clinical studies, the American Cardiology Association and American Heart
Association have produced guidelines for the management of patients with acute myocardial
infarction. In these guidelines, they divide various diagnostic procedures and treatments
into three classes, of which class 1 shows positive evidence for its use and effect, class 2
shows conflicting evidence, and class 3 shows negative evidence. These guidelines propose
recommendations and help clinicians’ decision-making3). Although these guidelines are
based on many clinical studies examining cost-effectiveness as well as short-term outcomes
and long-term prognoses, such a randomized trial has some serious problems, such as cost
in both money and time, generalizing from a specific kind of patient to other patients, and
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ethical problems arising when patients might be randomized out of a treatment suspected
to be effective4). Instead of a randomized control study, one study uses observational
data from patients’ medical records and investigates the incremental effects of intervention
therapy for acute myocardial infarction by using the distance between their houses and
hospitals as valid instrumental variables5).
Some researchers point out that the effects of treatments with high fixed and marginal
costs, such as operations and coronary interventions, are over-estimated. Treatments for
ischaemic heart disease include low technical innovations with low fixed and marginal costs,
such as aspirin or β-blockers, as well as the use of advanced technical innovations. One
study concludes that both low and high technical interventions contributed significantly
to the improvements of ischaemic heart disease6), and another found that low technical
innovations probably accounted for the bulk of the heart attack mortality decline between
1975 and 19957).
Unfortunately, in Japan, no large randomized controlled studies have been carried out,
and no treatment guidelines based on many clinical studies have been established. Clin-
icians usually make decisions on diagnostic procedures and treatments with the aim of
improving in-hospital prognoses, and make decisions without consideration of costs. Need-
less to say, clinical decision-making must not only be grounded on evidence from published
articles, but also on each clinician’s experience and each patient’s conditions. Considering
the differences of outcomes of surgery or intervention therapy for ischaemic heart disease
among medical providers and the need for efficient use of medical resources, large clinical
studies are needed in Japan.
With this background, this paper examines outcomes of the treatment for ischaemic
heart disease using observational microdata of the SMC gathered from claim data.
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2 Data
The data are from Surveys of Medical Care (SMC), which are conducted every year in June
by the Ministry of Health and Welfare. The surveys are stratified samples of approximately
200,000 claims data from the government-managed health insurance and national health
insurance scheme, written by medical providers all over Japan. Although it is the most
comprehensive survey of medical care in Japan, there are several problems with the SMC
for research.
First, the survey is only conducted in June and does not cover all patients. Because
there are not enough samples, the data are pooled for several years.
The second problem is the coding used for each disease and drug. With the disease clas-
sification, ischaemic heart disease consists of one group, but this corresponds to I20–I25 in
ICD-10. This includes I20, Angina pectoris; I21, Acute myocardial infarction; I22, Subse-
quent myocardial infarction; I24, Other acute ischaemic heart diseases; and I25, Chronic
ischaemic heart disease. From the SMC, acute myocardial infarction cannot be distin-
guished from chronic ischaemic heart diseases such as stable angina. With the coding of
drugs, the SMC shows only a four-digit classification combining drug code and drug price
determined by the government. However, many generic drugs have the same prices, and
thus it is impossible to isolate them.
The third problem is related to the first one. The SMC uses a sample from claim data
during one month, and there is no information about previous months and the following
months, even if th sampled patients were in hospital dring the other months. From the
Patient Survey of the Ministry of Health and Welfare, the duration of hospitalization of
the ischaemic heart disease patient is 31.3 days on average. However, many patients have
hospitalization across months.
The fourth problem is that the SMC is based on claim data, not on patients’ clinical
cards. In the clinical setting, physicians and other medical providers record everything
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on the patient’s clinical card. Using clinical cards, clerical workers make claim data for
charging fees to insurers once a month. In claim data, clinical procedures are recorded
comprehensively, not chronologically. In other words, there is no information about the date
of the specified procedures, even though the information about drugs, tests and treatments
performed are almost perfect. Furthermore, the SMC does not indicate death, discharge
or continuation of therapy.
Owing to these problems, the SMC is not suited for analysis of the long-term prognosis
and medical expenditure of hospitalization periods longer than one month. Hence, it is
important to specify proxy variables that represent short-term outcomes and analyse the
effects of operations and coronary interventions for ischaemic heart disease. The compared
operations are CABG and coronary interventions such as PTCA. Additionally, preserv-
ing treatments with invasive procedures for the patients of ischaemic heart disease with
emergent and intensive care are compared.
3 Comparisons between outcome of CABG with
coronary interventions
First, CABG and coronary interventions such as PTCA are compared. The samples are
the patients for which the diagnosis is ischaemic heart disease and coronary angiography
is performed. Ischaemic heart disease is caused by stenosis or occlusion of the coronary
artery supporting the heart muscle. Coronary angiography shows the pathological regions
of the coronary artery, wall motion of the heart and haemodynamics of the heart in detail,
and is always done before CABG and PTCA. By sampling the patients with coronary
angiography from all the patients, samples in which patients’ condition are so stationary
that angiography is not needed, or so severe that invasive procedures such as angiography
are impossible, are excluded. Note that, as for the second problem mentioned above, many
cases are chronic, not acute. To exclude chronic cases, the data are limited to patients with
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hospital stay less than one month, and with blood type tests in the corresponding month.
Since blood type tests are always done at the first admission and not at readmission or
re-operation, this indicates the first procedure in the hospital. By adding each constraint,
the sample can be limited to patients in which the period from admission to corresponding
treatment is short, and chronic cases can be excluded.
In this analysis, data include heterogeneous patients, and treatments are selected en-
dogenously, not exogenously, as in a randomized control study. Corresponding to this
endogeneity, we provide an account in ’the model’ section.
Although PTCA corresponds to the usual balloon angioplasty (POBA) in the SMC, there
are new devices such as the directional coronary atherectomy (DCA) and the transluminal
extraction catheter (TEC). However, PTCA here is broadly defined as usual balloon an-
gioplasty and other various new devices, because the data cannot provide information to
distinguish them.
Finally, the adopted outcome measures are explained. The most important factor deter-
mining the short-term prognosis is pump function of the heart. Killip’s classification8) is
the most classical, but Forrester’s classification is broadly used in deciding treatment, in
relation to patients’ heart function9). In this classification, catecolamines are recommended
for treatment of severe heart failure. Among catecolamines, dopamine and dobutamine are
used most widely for heart failure, and norepinephrine and epinephrine produce such a
strong constriction of peripheral vessels that they are not used as the first choice drug, but
used for cases with the most severe malfunction of the heart. In particular, epinephrine is
usually used for cardiac arrest. Accordingly, using of norepinephrine or epinephrine indi-
cates that a patient has severe heart failure. As norepinephrine and epinephrine have the
same code and price, there is no way to distinguish them.
From the fourth problem, the patients using these drugs include the ones before and after
treatment. Thus, the patients in which heart failure has been very severe before treatment
cannot be excluded, but uncompensated heart failure is one of the contra-indications for
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coronary angiography10). We assume that a few patients were using these drugs for ad-
vanced coronary angiography.
To sum up, the use of norepinephrine or epinephrine is a proxy variable for severe heart
failure, and we compare the effect of the PTCA with CABG on severe heart failure.
4 Comparison between outcome of preserving pro-
cedures with invasive procedures
The sample used cases with emergent or intensive treatments, and we compared invasive
procedures with preserving treatments. To do this, the following procedure was adopted.
First, the sampled cases were refined so that the hospitalization fee was for the emergency
ward or intensive care unit, so as to limit acute cases and chronic patients managed to just
after operations such as CABG. Moreover, to exclude chronic cases, hospitalization less
than one month and blood type tests in this are required. The outcome measure for severe
heart failure is the same.
5 Estimation model
When using observational data, it is extremely important that selections of treatment are
determined not exogenously, as in a randomized controlled study, but endogenously. To
treat this problem of endogeneity, preceding investigations have used the distance between
patients’ houses and hospitals as an instrumental variable in evaluating the effect of cardiac
catheterization from the 180,000 patients’ records of acute myocardial infarction in the
US11).
On the other hand, the problem of endogeneity is often raised in econometrics. Although
the instrumental variables method is used to solve this, the nonparametric propensity score
matching method12),13) is widely employed and recognized for its advantages14). It has now
begun to be used in the analysis of treatment effects in the field of health economics15). In
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this paper, both the nonparametric propensity score matching method and instrumental
variables methods are employed and compared for evaluation of treatment effects.
The nonparametric propensity score matching method is explained as follows. Consider
patients with certain treatments or procedures i and j. Information on respective patients
is denoted by Xi and Xj , treatment outcome of respective patients by Yi and Yj . The first
stage in estimation is probit estimation with regard to treatment selection. The estimated
participation probabilities of each types are denoted as P (Xi) and P (Xj). Then, the
treatment effect is evaluated as:
∑
i{Yi −
∑
j
YjK[(P (Xi)−P (Xj))/h]∑
j
K[(P (Xi)−P (Xj))/h] }
N
(1)
whereK[·] denotes the kernel estimator, and the Epanechnikov, biweight, triangular, Gaus-
sian, Rectangular procedures are used16). h is set 0.9σP (Xj)N
−0.2, which is regarded as the
optimal value, and σP (Xj) denotes the standard deviation of P (Xj). N denotes sample size.
This procedure is called kernel matching.
However some investigators recommend local linear matching rather than kernel match-
ing with respect to efficiency17). This method is explained as:
∑
i{Yi −
∑
j
Yj{Kij
∑
k
Kik(P (Xi)−P (Xk))2−Kij(P (Xi)−P (Xj))
∑
k
Kik(P (Xi)−P (Xj))}∑
j
Kij
∑
k
Kik(P (Xi)−P (Xk))2−(
∑
k
Kik(P (Xi)−P (Xk))2 }
N
(2)
where Kij = K[(P (Xi)−P (Xj))/h] and k denotes the summation of patients undertaking
a certain treatment. Statistics estimated using equation (1) or (2) are called generically
average treatment effects.
Further, the distributions of the average treatment effects are not specified. Accordingly,
their confidence intervals are calculated using bootstrapping. Concretely, replication is
done 1,000 times and bias correction is used16.
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5.1 Estimation model for comparison of PTCA and CABG
The explained variable is dichotomous, being 1 when either of two drugs is used and 0
when not used. Explanatory variables are patients’ characteristics such as age and sex,
providers’ information such as number of beds in the hospital, type of hospital (non-profit,
profit and public) and whether teaching hospital, and dichotomous treatment variables,
being 1 when PTCA is performed and 0 when CABG is performed.
5.2 Estimation model for comparison between invasive proce-
dures and preserving procedures
Almost all of the estimation equations are the same as in the previous subsection except for
the treatment variables. The dichotomous variable is 1 when invasive procedures (PTCA
or CABG or coronary angiography) are performed, and 0 otherwise.
6 Estimation result for comparison between PTCA
and CABG
Table 1 shows the average of each sample, and Tables 2–5 indicate the estimation re-
sults from the whole sample. Tables 6–9 show results from data of less than one month
hospitalization. As there were insufficient observations for the sample with blood type
test, we omitted that estimation. Each sample produced results of the probit estimation,
regressing outcome on treatment (PTCA or CABG) and other variables (Tables 2, 6),
probit estimation for treatment selection (Tables 3, 7), probit estimation for outcome us-
ing estimated probability of treatment selection as instrumental variables (Tables 4, 8),
and average treatment effect constructed by the nonparametric propensity score matching
method using estimated probability of PTCA choice as P .
In simple probit estimation without consideration of endogeneity (Table 2), age and for-
profit hospitals are significantly positive, and PTCA, age-squared and teaching hospital
are significantly negative. The probability of severe heart failure increases until about 75
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years of age, and then decreases. For-profit hospitals have higher probability of severe heart
failure for their patients than public hospitals, and teaching hospitals have a lower proba-
bility than other hospitals. Most importantly, PTCA has a significantly lower probability
of severe heart failure than CABG, by an amount of 35 percentage points. This means
that PTCA reduces the probability of severe heart failure to 15% if it supposed to be a
probability of severity of 50%
However, the choice of treatment should be an endogenous variable determined by vari-
ous properties of patients and hospitals. In our data, we do not have detailed information
of these properties, and thus this information is consigned to the error term, and all of the
estimators have biases due to correlation between the error term and treatment selection.
To examine such bias, Table 4 shows estimation results from the instrumental variables
method. Comparing Table 4 and the result of simple estimation (Table 2), positive signif-
icance in for-profit hospitals and negative significance in PTCA and teaching hospital do
not change. However, age, significant in Table 2, is not significant in Table 4; conversely,
the number of beds, not significant in Table 2, is negatively significant in Table 4. PTCA
has a more significantly lower probability of severe heart failure than CABG by 45 percent-
age points, and the direction of bias from the endogeneity seems to be zero. This result is
confirmed also in Table 5 using the nonparametric propensity score matching method, and
is robust from the definition of the kernel. Since the advantage of PTCA compared with
CABG is 26% compared with 33% in this table , it is a little weaker than the instrumental
variables results.
Table 6 indicates the result of simple estimation with less than one month hospitalization.
This shows that age and for-profit hospitals are significantly positive and age-squared is
significantly negative. These are almost the same as for the whole data set. PTCA is
negative but not significant. In other words, PTCA has a lower probability of severe
heart failure, but the difference is not significant. The advantage is only eight percentage
points, and much lower than for the whole data set. Estimation using the instrumental
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variables method (Table 8) has almost the same result as in Table 6, and PTCA is negative
but not significant. In the nonparametric propensity score matching method, the signs of
the coefficients depend on the definition of the kernel. PTCA has a lower probability
of severe heart failure than CABG for two kernels and no significant difference for the
others. In the former cases, PTCA reduces the probability of severe heart failure by 9–31
percentage points, and this difference is smaller than for the whole data set. Note that some
reservations are needed in interpretation because of the instability of the results. This may
due to be poorness-of-fit in estimation in treatment selection caused by a small number of
observations.
To sum up, the advantage of PTCA over CABG cannot be denied, but with reser-
vations. Even in the case of lack of fit in the treatment selection without a significant
relationship, the nonparametric propensity score matching method results are significant
in some cases compared with the instrumental variables method approach. This may imply
the methodological superiority of nonparametric propensity score matching method over
the instrumental variables method.
7 Estimation results of a comparison between inva-
sive procedures and preserving procedures
Next, we compare invasive procedures and preserving procedures for patients with inten-
sive or emergency care. Estimations are performed on the whole data set and restricted
data sets (with less than one month hospitalization or blood type test). Tables 11–14 in-
dicate the estimation results for the whole sample, Tables 15–18 the results for less than
one month hospitalization , and Tables 19–22 the results for blood type test. Each sample
produces estimation results of probit estimation of outcome on treatment selection (inva-
sive procedures or preserving procedures) and other variables (Tables 11, 15, 19), probit
estimation for treatment selection (Tables 12, 16, 19), probit estimation of outcome on
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estimated probability of treatment selection as instrumental variables (Tables 13, 17, 21),
and average treatment effects constructed by the nonparametric propensity score matching
method using the estimated probability of invasive procedures as the choice of P (Tables
14, 18, 22).
In the simple probit estimation without consideration of endogeneity (Table 11) and
with the instrumental variable method (Table 13), there are no significant variables. Even
though both are insignificant, invasive procedures increase the probability of severe heart
failure in the simple probit estimation, and decrease it with the instrumental variables
method. On the other hand, the nonparametric propensity score matching method does
not show any significant effect except with one kernel. In this kernel, invasive procedures
increase the probability of severe heart failure significantly by about seven percentage points
compared with preserving procedures.
Table 15 indicates the results of simple estimation using the data for less than one month
hospitalization. The number of beds and for-profit hospitals are significantly negative.
Invasive procedures is negative but not significant; that is, invasive procedures have a lower
probability of severe heart failure, but this difference is not significant. The estimation
results using the instrumental variables method (Table 16) have no significant coefficients,
but invasive procedures have a significantly lower probability of severe heart failure than
preserving procedures. For the nonparametric propensity score matching method, Table
17 shows that the signs of the coefficients are mixed across the kernels. Invasive procedures
have a lower probability of severe heart failure than preserving procedures in two cases,
but no significant difference in three cases. In the former cases, the differences are 7–9
percentage points, and are inconsistent with the case for the whole data set.
Table 18 indicates the result of a simple probit estimation using the data with blood type
test, and this shows that non-profit hospital is significantly negative. Invasive procedures
have a lower probability of severe heart failure, but this is not significant. The instrumental
variables method results in Table 20 show that female, teaching hospital and invasive
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procedures are significantly negative, and thus invasive procedures decrease the probability
of severe heart failure by 20 percentage points, in comparison with preserving procedures.
In contrast, for the nonparametric propensity score matching method results shown in Table
21, invasive procedures have a higher probability of severe heart failure than preserving
procedures for all kernels, and the difference is 9–16 percentage points.
The results of comparison between invasive procedures and preserving procedures are
summarized as follows. With the instrumental variables method, there is no significant
difference between the two procedures for the whole sample and the less than one month
hospitalization sample, but predominance of invasive procedures over preserving procedures
in the sample with blood type test is indicated. For the nonparametric propensity score
matching method, results show a lack of robustness for the whole sample and less than
one month hospitalization sample, and we found superiority of preserving procedures over
invasive procedures in the blood type test sample regardless of kernel. The predominance
of these two procedures is unstable across sample definition, and thus estimation interpre-
tations should be made carefully. The results of the instrumental variables method and the
nonparametric propensity score matching method are inconsistent, and thus the usefulness
of the instrumental variable method seems to be limited.
8 Concluding remarks
Using microdata of the SMC based on observational patient data, this paper compares the
outcomes of patients with ischaemic heart disease between PTCA and CABG, or of patients
with intensive or emergent care between invasive procedures and preserving procedures.
Taking endogeneity of treatment selection into consideration, the instrumental variables
and nonparametric propensity score matching methods are employed for estimation. We
found that there is no case in which both methods are consistent regarding significance. Of
five sample sets (two from section 6 and three from section 7), one sample set (the sample set
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with blood type tests in comparison of invasive procedures with preserving procedures) has
opposite results between the two methods: the nonparametric propensity score matching
method results show that invasive procedures have a significantly higher probability of
severe heart failure than preserving procedures, but the instrumental variables method
shows the opposite result.
However, the nonparametric propensity score matching method seems to be more flexible
than the instrumental variables method in general. Moreover, the theoretical advantages
of the nonparametric propensity score matching method over the instrumental variable
method are well known. If we believe the results of the nonparametric propensity score
matching method, PTCA has a significantly lower probability of severe heart failure than
CABG, with some reservations, and invasive procedures have a significantly higher proba-
bility of severe heart failure than preserving procedures in the blood type test sample.
These results contain two important reservations. Firstly, there are several problems
with the SMC as described in Section 2. These data take samples from clinical records in
hospitals all over Japan, and report all medical procedures. This kind of data is unique
compared with other countries. However, there is only a little information about diseases or
patients’ conditions. Thus, clinical outcome has to be inferred from corresponding clinical
procedures. This procedure depends heavily on some assumptions, in cases where the order
of the clinical procedures is unknown.
The second problem is endogeneity of treatment selection. Two estimation methods are
employed, but the results are not robust between the methods. This seems to be caused
by insufficient information about the clinical course, pathological lesion, detailed heart
function and so forth, and we cannot control these factors, which are closely related to
treatment selection. A more organized and complicated nonparametric propensity score
matching method should overcome this informational limitation in the future.
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Table 1: Averages
All
samples
Less than
one month
hospital-
ization
sample
Severe Heart Failure .354067 .2876254
PTCA .6220096 .6822742
Age 64.09569 64.08027
Female 1.232057 1.200669
Number of Beds?Log? 6.366292 6.276663
Non-profit Hospital .1028708 .1036789
For-profit Hospitals .2416268 .2073579
Teaching Hospital .2105263 .1672241
Note: The number of samples is 223 in all samples, and 152 in samples less than One
Month Hospitalization.
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Table 2: Estimation Results by Simple Probit (All Samples)
Estimates z-value P-value Marginal Effect
Age .5966369 2.278 0.023 .17839615
Age2 -.0042646 -2.089 0.037 -.00127514
Female .1824614 0.402 0.688 .07255956
PTCA -1.271928 -2.941 0.003 -.3625063
Number of Beds ?Log? -.0839713 -0.217 0.828 -.02510766
Non-profit Hospital -.6163245 -1.145 0.252 -.2185034
For-profit Hospital .9385328 2.336 0.019 .34456916
Teaching Hospital -1.023907 -1.915 0.055 -.31989167
? Constant???? -19.25944 -2.218 0.027
Note: The log likelihood is -118.22913, and quasi R2 is 0.2338. The null hypothesis that
all variables except with constant are 0 is rejected under 10% significant level.
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Table 3: Estimation Results of Treatment Selection (All Samples)
Estimates z-value P-value Marginal Effect
Age -.0469925 -0.231 0.818 -.0146637
Age2 .0003431 0.211 0.833 .00010706
Female -.0164387 -0.034 0.973 -.00554354
Number of Beds?Log? -.6521113 -1.565 0.118 -.20348711
Non-profit Hospital -.0280082 -0.052 0.959 -.00947649
For-profit Hospital .8226628 2.079 0.038 .19909877
Teaching Hospital -.5034769 -1.020 0.308 -.18805565
? Constant???? 6.16708 0.849 0.396
Note: The of likelihood is -122.61888, and quasi R2 is 0.1112. The null hypothesis that all
variables except with constant are 0 is rejected under 10% significant level.
20
Table 4: Estimation Results for Outcome using Instrumental
Variable Method (All Samples)
Estimate z-value P-value Marginal Effect
Age .372029 1.415 0.157 .12358848
Age2 -.0026644 -1.307 0.191 -.0008851
Female .0387424 0.083 0.934 .01539951
PTCA Selecting Probability(Estimates? -9.112694 -2.037 0.042 -.45850835
Number of Beds?Log? -1.335078 -1.778 0.075 -.44351456
Non-profit Hospital -.324814 -0.665 0.506 -.12454906
For-profit Hospitals 2.679349 2.639 0.008 .53648192
Teaching Hospital -2.238602 -2.381 0.017 -.44893838
? Constant???? 1.680618 0.144 0.886
Note: The log likelihood is -130.34474, and quasi R2 is 0.1553. The null hypothesis that
all variables except with constant are 0 is rejected under 10% significant level.
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Table 5: Estimation Results for Outcome using Nonparametric
Propensity Score Method (All Samples)
Kernel Average 95%CI Upper 95%CI Lower
Epanechnikov -.3262025 -.4336698 -.2349667
Biweight -.6030771 -1.73575 -.197184
Triangular -.3283879 -.4264668 -.2277659
Gaussian -.2558149 -.3311637 -.1775348
Rectangular -.2674383 -.3735231 -.1592936
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Table 6: Estimation Results without accounting for Endogeneity
(Less than One Month Hospitalization Samples)
Estimates z-value P-value Marginal Effect
Age 1.566249 2.189 0.029 .41259756
Age2 -.0112827 -2.165 0.030 -.00297222
Female -.3810702 -0.805 0.421 -.08747231
PTCA -.3374903 -0.611 0.541 -.07921911
Number of Beds?Log? -.6504081 -1.131 0.258 -.17133729
Non-profit Hospital -.7992492 -1.290 0.197 -.14610727
For-profit Hospital .9374392 2.005 0.045 .33579038
Teaching Hospital -.4971548 -0.689 0.491 -.10735859
? Constant???? -49.41318 -1.971 0.049
Note: The log likelihood is 699.40835, and quasi R2 is 0.2884. The null hypothesis that all
variables except with constant are 0 is rejected under 10% significant level.
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Table 7? Estimation Results of Treatment Selection?Less than
One Month Hospitalization? Samples ?
Estimates z-value P-value Marginal Effect
Age .3392646 1.237 0.216 .08025054
Age2 -.0028532 -1.323 0.186 -.0006749
Female .1156836 0.199 0.842 .02496931
Number of Beds?Log? -.1495782 -0.264 0.792 -.03538163
Non-profit Hospital -.1138539 -0.189 0.850 -.02772146
For-profit Hospital 1.403338 2.767 0.006 .13964116
Teaching Hospital -.6261293 -0.872 0.383 -.18888053
? Constant???? -8.272516 -0.822 0.411
Note:The log likelihood is 64.809806, and quasi R2 is 0.1416. The null hypothesis that all
variables except with constant are 0 is not rejected under 10
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Table 8? Estimation Results of Outcome using Instrumental
Variable Method?Less than One Month Hospitalization?
Samples?
Estimates z-value P-value Marginal Effect
Age 2.096679 2.581 0.010 .53839867
Age2 -.0155398 -2.553 0.011 -.0039904
Female -.212923 -0.423 0.673 -.05045125
PTCA Choosing P-value?Estimates? -5.3015 -1.313 0.189 -.18025783
Number of Beds?Log? -.6767463 -1.137 0.256 -.17377923
Non-profit Hospital -.878099 -1.452 0.147 -.14372993
For-profit Hospital 2.382303 1.872 0.061 .74867916
Teaching Hospital -1.279259 -1.257 0.209 -.16612725
? Constant??? -61.99018 -2.338 0.019
Note:The log likelihood is 68.383353, and quasi R2 is 0.3043. The null hypothesis that all
variables except with constant are 0 is not rejected under 10% significant level.
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Table 9: Outcome Estimates using Nonparametric Propensity
Score Method (Less than One Month Hospitalization? Samples)
Average 95% CI Upper 95% CI Lower
Epanechnikov -.0170832 -.1503817 .1186205
Biweight -.0926619 -.1833897 -.0032472
Triangular -.0733864 -.1926208 .0522043
Gaussian -.3057324 -.4355384 -.1637794
Rectangular .0194312 -.1149288 .1604738
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Table 10: Averages
All
Samples
Less than
One
Month
Hospital-
ization ?
Samples
Blood
Type Test
Samples
Severe Heart Failure .2 .1795717 .2071006
Invasive Procedures .4864198 .4629325 .4319527
Age 66.58148 65.24547 65.88462
Female 1.398765 1.357496 1.45858
Number of Beds?Log? 6.255634 6.283452 6.227614
Non-profit Hospital .0567901 .0560132 .0710059
For-profit Hospital .3 .3212521 .2899408
Teaching Hospital .2802469 .2784185 .2781065
Note: The number of samples is 447 in all samples, 345 in Less than One Month Hospital-
ization? Samples and 193 in Blood Type Test Samples.
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Table 11?Estimation Results of Simple Probit?All Samples?
Estimates z-value P-value Marginal Effect
Age .0741479 1.068 0.285 .02259805
Age2 -.0005246 -1.004 0.315 -.00015989
Female -.2150448 -0.767 0.443 -.06286574
Invasive Procedures .0131575 0.046 0.963 .00418386
Number of Beds?Log? -.1300969 -0.817 0.414 -.03964964
Non-profit Hospital .6017939 1.352 0.176 .2205717
For-profit Hospital -.371838 -1.166 0.243 -.10180657
Teaching Hospital .0640221 0.185 0.854 .02070098
? Constant???? -2.005997 -0.801 0.423
Note:The log likelihood is 241.63305, and quasi R2 is 0.0597. The null hypothesis that all
variables except with constant are 0 is not rejected under 10% significant level.
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Table 12?Estimation Results of Treatment Selection?All
Samples?
Estimates z-value P-value Marginal Effect
Age .0446887 0.761 0.447 .01593775
Age2 -.0003181 -0.712 0.476 -.00011343
Female -.3432881 -1.280 0.201 -.13144744
Number of Beds?Log? .2528266 1.739 0.082 .09016785
Non-profit Hospital -.9171804 -2.177 0.030 -.30588178
For-profit Hospital -.7173538 -2.446 0.014 -.2534792
Teaching Hospital -.2130057 -0.660 0.510 -.08306005
? Constant???? -2.148546 -0.973 0.331
Note:The log likelihood is 279.65664, and quasi R2 is 0.0947. The null hypothesis that all
variables except with constant are 0 is rejected under 10% significant level.
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Table 13? Estimation Results of Outcome using Instrumental
Variable Method?All Samples?
Estimates z-value P-value Marginal E
Age .5793714 1.275 0.202 .17255549
Age2 -.0041362 -1.274 0.203 -.00123189
Female -4.087484 -1.202 0.229 -.23439953
Invasive Procedures Choosing P-value?Estimates? -31.31108 -1.161 0.246 -.23440028
Number of Beds?Log? 2.542564 1.070 0.285 .75725776
Non-profit Hospital -10.13291 -1.088 0.277 -.23440028
For-profit Hospital -8.998187 -1.220 0.222 -.23440028
Teaching Hospital -2.039323 -1.032 0.302 -.23154326
? Constant???? -9.269772 -1.226 0.220
Note:The log likelihood is 236.679, and quasi R2 is 0.0790. The null hypothesis that all
variables except with constant are 0 is not rejected under 10% significant level.
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Table 14? Estimation Results of Outcome using Nonparametric
Propensity Score Method?All Samples?
Average 95% CI Upper 95% CI Lower
Epanechnikov .0690913 .010771 .1381654
Biweight .0019177 -.0558639 .0623594
Triangular .0623893 -.0016824 .120463
Gaussian .0057966 -.0521428 .0693814
Rectangular .0239519 -.0337745 .0846671
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Table 15?Estimation Results of Simple Probit?Less than One
Month Hospitalization? Samples ?
Estimates z-value P-value Marginal Effect
Age .0401907 0.487 0.627 .01056798
Age2 -.000204 -0.314 0.754 -.00005364
Female -.1112446 -0.343 0.732 -.02923743
Invasive Procedures -.2025692 -0.615 0.539 -.05100845
Number of Beds?Log? -.4093291 -1.647 0.100 -.10763148
Non-profit Hospital .3665715 0.761 0.447 .11612355
For-profit Hospital -.8165761 -2.023 0.043 -.14845607
Teaching Hospital .444591 0.828 0.408 .14421667
? Constant???? .4466926 0.143 0.886
Note:The log likelihood is 162.79032, and quasi R2 is 0.1112. The null hypothesis that all
variables except with constant are 0 is rejected under 10% significant level.
32
Table 16?Estimation Results of Treatment Selection?Less than
One Month Hospitalization? Samples?
Estimates z-value P-value Marginal Effect
Age .0829551 0.922 0.357 .02864868
Age2 -.0006732 -0.941 0.347 -.00023249
Female -.6441801 -2.117 0.034 -.21512405
Number of Beds?Log? .2396488 1.211 0.226 .08276313
Non-profit Hospital -.6660112 -1.471 0.141 -.22088191
For-profit Hospital -.6470829 -1.855 0.064 -.21589624
Teaching Hospital -.2074055 -0.494 0.621 -.07747569
Constant -2.836181 -0.892 0.372
Note:The log likelihood is 209.61745, and quasi R2 is 0.1045. The null hypothesis that all
variables except with constant are 0 is rejected under 10% significant level.
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Table 17? Estimation Results of Outcome using Instrumental
Variable Method ?Less than One Month Hospitalization?
Samples?
Estimates z-value P-value Marginal E
Age .1928973 0.809 0.418 .05067594
Age2 -.0014347 -0.753 0.451 -.0003769
Female -1.57529 -0.734 0.463 -.18584387
Invasive Procedures Choosing P-value?Estimates? -6.635654 -0.704 0.482 -.19315464
Number of Beds?Log? .1059676 0.140 0.889 .0278387
Non-profit Hospital -1.190768 -0.511 0.610 -.17331625
For-profit Hospital -2.403003 -1.035 0.301 -.19261563
Teaching Hospital .0349378 0.045 0.964 .00972145
? Constant???? -1.528419 -0.357 0.721
Note:The log likelihood is 162.84529, and quasi Rα is 0.1109. The null hypothesis that all
variables except with constant are 0 is rejected under 10% significant level.
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Table 18?Estimation Results of Outcome using Nonparametric
Propensity Score Method?Less than One Month Hospitalization
? Samples?
Average 95% CI Upper 95% CI Lower
Epanechnikov -.0644408 -.1277267 .0080246
Biweight -.0884281 -.1482805 -.0256893
Triangular -.0596314 -.1262428 .0085508
Gaussian -.072562 -.1380501 -.0053486
Rectangular -.044513 -.1040212 .0212697
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Table 19?Estimation Results of Simple Probit?Blood Type Test
Samples?
Estimates z-value P-value Marginal Effect
Age .024964 0.260 0.795 .00637125
Age2 -.0001039 -0.145 0.885 -.00002651
Female -.5475136 -1.116 0.264 -.12213132
Invasive Procedures -.2815678 -0.647 0.517 -.07170522
Number of Beds?Log? -.2903051 -1.138 0.255 -.074091
Non-profit Hospital 1.404206 2.377 0.017 .51501181
For-profit Hospital -.5313012 -0.822 0.411 -.11951618
Teaching Hospital .3107833 0.562 0.574 .10007992
? Constant???? .6818123 0.177 0.859
Note:The log likelihood is 88.747851, and quasi R2 is 0.1716. The null hypothesis that all
variables except with constant are 0 is not rejected under 10% significant level.
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Table 20?Estimation Results of Treatment Selection?Blood
Type Test Samples?
Estimates z-value P-value Marginal Effect
Age .2601578 1.838 0.066 .08028642
Age2 -.0020923 -1.865 0.062 -.0006457
Female -1.248489 -2.882 0.004 -.36477547
Number of Beds?Log? .4424047 1.421 0.155 .136529
Non-profit Hospital -.5958351 -0.977 0.329 -.21450428
For-profit Hospital .2633366 0.432 0.666 .10475259
Teaching Hospital -1.568982 -2.367 0.018 -.40426955
? Constant???? -8.14102 -1.652 0.098
Note:The log likelihood is 105.12992, and quasi R2 is 0.2140. The null hypothesis that all
variables except with constant are 0 is rejected under 10% significant level.
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Table 21: Estimation Results of Outcome using Instrumental
Variable Method (Blood Type Test Samples)
Estimates z-value P-value Marginal
Age .3454181 1.669 0.095 .07855998
Age2 -.0026482 -1.636 0.102 -.0006022
Female -2.437649 -2.882 0.004 -.1922997
Invasive Procedures Selecting Probability(Estimate) -6.041505 -2.752 0.006 -.1927740
Number of Beds(Log) .0093336 0.041 0.967 .00212279
Non-profit Hospital .1712881 0.238 0.812 .05030541
For-profit Hospital -.4380939 -0.668 0.504 -.0969659
Teaching Hospital -1.611602 -2.509 0.012 -.1861923
? Constant??? -4.382809 -0.859 0.391
Note: The log likelihood is 79.3828, and quasi R2 is 0.2590. The null hypothesis that all
variables except with constant are 0 is rejected under 10% significant level.
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Table 22? Estimation Results of Outcome using Nonparametric
Propensity Score Method?Blood Type Test Samples?
Average 95% CI Upper 95% CI Lower
Epanechnikov .1223203 .0416913 .214348
Biweight .0874121 .0143986 .1618662
Triangular .1621314 .0793257 .2544301
Gaussian .0944667 .0232313 .1762032
Rectangular .1441248 .0517966 .2363143
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